This overview highlights advancements in antibody-based PET tracers for precision diagnostics in neurodegenerative diseases, indicating their potential to improve neuroimaging.
To summarize the current advances, molecular engineering principles, and translational progress of antibody-based positron emission tomography (PET) tracers specifically optimized for neuroimaging, with a focus on overcoming blood–brain barrier (BBB) limitations and enabling precision diagnostics in neurodegenerative diseases.
No takes yet. Share an insight, caveat, or question.
Paez-Garcia et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: